The main therapeutic agents for congenital hyperinsulinemia include diazoxide and octreotide. Diazoxide is the drug of choice for the treatment of congenital hyperinsulinemia. It is usually tried for 7-10 days after the diagnosis of the child. The dose range: 5-15 mg/kg/day to see if the child is effective on diazoxide treatment. If the child does not respond to diazoxide, octreotide may be used as the next treatment. The dose range is: 5-20ug/kg/day. Most children who do not respond to diazoxide therapy will respond to octreotide. However, the drug is expensive, requires multiple daily subcutaneous injections for administration, and tends to develop rapid tolerance, which greatly limits its widespread and long-term clinical use.